Please assess the completion status of the following clinical trial:

Trial Title: Study in Healthy Volunteers to Prove That Two Different Formulations of Rotigotine Patches Deliver Equivalent Drug Amount to the Body

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy White, male volunteers between 18 and 55 years of age (inclusive).~* BMI between 19 and 28 kg/m\^2 (inclusive)~Exclusion Criteria:~* Previous participation in a clinical study with Rotigotine~* History or current condition of epilepsy and/or seizures~* Known clinically relevant allergy or known/suspected clinically relevant drug hypersensitivity~* History of significant skin hypersensitivity to adhesives or other transdermal products or recently unresolved contact dermatitis~* History or present condition of an atopic or eczematous dermatitis, psoriasis, and/or an active skin disease~* Clinically relevant abnormality in physical examination, ECG, vital signs or safety laboratory examinations~* Positive HIV, hepatitis B or C test or positive alcohol or drug test~* Relevant hepatic or renal dysfunction~* Intake of medication that might interfere with the test drug within 2 weeks prior to dosing

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Rotigotine PR2.2.1 first (Type: EXPERIMENTAL): Rotigotine transdermal patch 4.5 mg/10 cm\^2, test drug product PR2.2.1 followed by Rotigotine transdermal patch 4.5 mg/10 cm\^2, reference drug product PR2.1.1 separated by a washout phase of at least 5 days
- Rotigotine PR2.1.1 first (Type: EXPERIMENTAL): Rotigotine transdermal patch 4.5 mg/10 cm\^2, reference drug product PR2.1.1 followed by Rotigotine transdermal patch 4.5 mg/10 cm\^2, test drug product PR2.2.1 separated by a washout phase of at least 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).